BAX INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Baxter International, Inc.

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the safety and performance of its Novum LVP device, which has been linked to serious patient risks and malfunctions [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP that led to malfunctions such as underinfusion and overinfusion, posing serious risks to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths associated with the Novum LVP but did not take adequate remedial measures [2]. - The company issued warnings to customers about the risks but continued to face issues with the device, leading to a temporary halt in shipments and installations [3]. Group 2: Financial Impact - Following the announcement of safety concerns and the decision to pause shipments, Baxter's stock price fell by $6.29, approximately 22.4%, from $28.05 to $21.76 on July 31, 2025 [3].